Allarity Q2: $26.9M Cash, $20M Debt, and a CLIA Lab Milestone
ALLR sits 85% above its 52-week low of $0.769.
Summary
Allarity reported Q2 2026 results with $26.9M in cash and restricted cash, a $3.4M net loss, and $20.9M in promissory note debt. The company also announced CLIA certification for its Denmark lab.
Key Events · Earnings and Guidance · ALLR
-
Q2 Net Loss of $3.4M
Net loss for Q2 2026 was $3.4 million, compared to $2.3 million in Q2 2025. Operating expenses fell 35% to $2.7 million, but interest expense rose to $0.7 million due to the new promissory notes.
-
Cash Position at $26.9M
Cash and restricted cash totaled $26.9 million as of June 30, 2026, including $10 million in restricted cash securing the B Note. Management expects this to fund operations for at least twelve months.
-
Streeterville Debt Totals $20.9M
The March 2026 Streeterville notes have a total outstanding balance of $20.9 million, including a $1.97 million monitoring fee. The A-1 Note bears 9% interest and matures September 2, 2027.
-
Tumim Equity Line Nearly Untapped
The $6.0 million Tumim equity line has only $2,000 drawn, leaving $5.998 million available. The purchase price is set at 95-97% of VWAP, subject to a 19.99% issuance limit.
Analysis · ALLR · Life Sciences
Allarity's Q2 2026 report shows a net loss of $3.4 million and a cash position of $26.9 million, including $10 million in restricted cash securing the Streeterville B Note. The company raised $20 million in March via promissory notes, but the A-1 Note carries a 9% interest rate and a $1.97 million monitoring fee, pushing total outstanding debt to $20.9 million. Management states cash is sufficient for at least twelve months, but the debt terms and ongoing losses keep liquidity risk elevated. The subsequent CLIA certification for the in-house lab is a positive operational step for stenoparib development.
At the time of this filing, ALLR was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.6M. The 52-week trading range was $0.77 to $2.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.